Clinical Trial Update: A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 feasibility and safety study of dual CD19/CD22 CAR-T cell therapy for CD19+CD22+ leukemia, with the trial currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Drugs mentioned

• Dual specificity CD19/CD22 CAR-T cell immunotherapy

Snippet

Sponsor: Seattle Children's Hospital | Conditions: Leukemia, Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING